What did @weightdoc actually say?
The creator walked through phentermine's history, mechanism, side effect profile, and its relationship to the banned fen-phen combination. The core claims: phentermine was FDA approved in 1959, it works as a sympathomimetic appetite suppressant similar to ADHD medications, it carries cardiovascular and psychiatric side effects, and it was only half of fen-phen. Critically, they stated that "the part that was responsible for the heart valve damage was the fenfluramine, not the phentermine." This is a lot of ground covered in a short video, and most of it holds up reasonably well.
The creator also noted that phentermine is a controlled substance, which complicates telehealth prescribing, and that it is generic and therefore relatively affordable. These are practical, accurate observations that are often left out of more clinical discussions.
Does the science back this up?
Largely yes, with a few areas worth scrutinizing more carefully. The 1959 FDA approval date is accurate. Phentermine's mechanism as a sympathomimetic amine that releases norepinephrine in the hypothalamus, suppressing appetite and increasing energy expenditure, is well established. The side effect list the creator gave, including anxiety, insomnia, hypertension, palpitations, and headache, matches what controlled trials and post-market surveillance have documented consistently.
On the fen-phen question, the science does support the creator's framing. The 1997 withdrawal of fenfluramine and dexfenfluramine was driven by echocardiographic findings of valvular abnormalities, not by phentermine data. Connolly et al. (1997, NEJM) identified cardiac valve disease in 24 of 24 patients who had taken fen-phen, with the serotonergic activity of fenfluramine implicated as the mechanism. Phentermine, which does not have significant serotonergic activity, was not found to independently cause valvular damage in that analysis.
Where the picture gets more complex is cardiac risk more broadly. Phentermine is not cardiac-neutral in all populations. Studies such as Weissman et al. (1998, NEJM) specifically examined valve regurgitation in fen-phen users, and while fenfluramine drove the signal, phentermine monotherapy data on long-term cardiac outcomes remain limited given its Schedule IV status has historically constrained long-duration trials.
What did they get wrong (or right)?
They got the fen-phen split right, and credit is due for being specific about it rather than vague. Too many clinicians conflate the two, and patients who hear "phentermine" often panic unnecessarily because of the fen-phen association. Clearing that up with accuracy matters.
The ADHD medication comparison is a reasonable analogy but slightly imprecise. Phentermine is structurally related to amphetamine but is not approved for ADHD, and its central nervous system stimulation profile differs from agents like methylphenidate or mixed amphetamine salts. Calling it "very much like an ADHD medication" risks creating a false equivalence that some patients may act on, for example by assuming it can substitute for their ADHD treatment.
The creator is appropriately cautious about uncontrolled hypertension and cardiac disease, which aligns with the FDA label. However, the video does not mention that phentermine is only FDA-approved for short-term use, typically 12 weeks or fewer, a point the FDA has maintained since approval. Many patients and even providers use it longer than that, and the evidence base for extended use is thinner than for newer agents like GLP-1 receptor agonists. That omission is worth flagging.
What should you actually know?
Phentermine is one of the most prescribed weight loss medications in the United States despite being 65 years old. Its affordability is a genuine advantage in a market now dominated by expensive branded injectables. But "old and cheap" is not the same as comprehensively studied. Because it is a Schedule IV controlled substance, it has historically been excluded from the kinds of long-term cardiovascular outcomes trials that have now been run for semaglutide, specifically the SELECT trial (Lincoff et al., 2023, NEJM), which showed cardiovascular risk reduction.
For patients with anxiety, insomnia, or uncontrolled blood pressure, the creator's caution is medically sound and not just conservative box-checking. The sympathomimetic mechanism is real, and those side effects are not rare. Phentermine also has abuse potential, which is why telehealth prescribing of it is more regulated than prescribing a non-controlled agent.
- Phentermine is FDA approved only for short-term obesity treatment, generally under 12 weeks, though off-label longer use occurs.
- It does not have the cardiovascular outcomes data that newer GLP-1 agents do.
- The fen-phen cardiac risk was attributable to fenfluramine, not phentermine, but phentermine is not without cardiovascular considerations.
- It is not a substitute for ADHD medications despite structural similarities to amphetamine.